agata janowska - Academia.edu (original) (raw)

Papers by agata janowska

Research paper thumbnail of Melanoma of the Penis: A Clinical Dermoscopic Case Study

Acta Dermato Venereologica, 2010

Research paper thumbnail of Reply to: “Skin damage among health care workers managing coronavirus disease 2019”

Journal of the American Academy of Dermatology, 2020

Research paper thumbnail of EUREKA study - the evaluation of real-life use of a biophotonic system in chronic wound management: an interim analysis

Drug design, development and therapy, 2017

Interest has grown regarding photobiomodulation (PBM) with low-level light therapy, which has bee... more Interest has grown regarding photobiomodulation (PBM) with low-level light therapy, which has been shown to positively affect the stages of the wound healing process. In a real-life context clinical setting, the objective of the EUREKA study was to investigate efficacy, safety, and quality of life associated with the use of a BioPhotonic gel (LumiHeal™) in the treatment of chronic wounds such as venous leg ulcers (VLUs), diabetic foot ulcers (DFUs), and pressure ulcers (PUs). This BioPhotonic gel represents a new, first-in-class emission spectrum of light, including fluorescence, to induce PBM and modulate healing. The multicenter, prospective, interventional, uncontrolled, open-label study enrolled 100 patients in 12 wound centers in Italy. We performed an early interim analysis based on the first 33 subjects (13 VLU, 17 DFU, 3 PU) in seven centers who completed the study. Seventeen patients (52%) achieved total wound closure (full re-epithelialization for 2 weeks) during the study...

Research paper thumbnail of Epidermal skin grafting in vitiligo: a pilot study

International Wound Journal, 2016

Vitiligo is a multifactorial acquired dermatosis characterised by achromic or hypochromic macules... more Vitiligo is a multifactorial acquired dermatosis characterised by achromic or hypochromic macules and by the absence of functioning melanocytes. Treatment depends on the extent of the affected areas and on disease activity. Surgical techniques have proven to be effective in stable cases but can be time-consuming and, in some cases, aesthetically unsatisfying or painful for the patients. The aim of the study was to assess the clinical safety and effectiveness of a new automatic epidermal skin harvesting device in patients with stable localised vitiligo over a minimum 12-month period. This new system (CELLUTOME™ Epidermal Harvesting System, KCI, an ACELITY Company, San Antonio, TX) is a commercially available epidermal skin harvesting system that can be used without local anaesthesia or other pre-treatments and has been shown to have low rates of donor site morbidity. Epidermal skin grafts can used in patients with acute and hard to heal chronic wounds, burns and stable vitiligo. The use of advanced therapies may improve the quality of life, have cost benefits and accelerate re-pigmentation of patients with vitiligo. In our preliminary study, this system was seen to be a safe and efficacious means of harvesting epidermal micrografts containing melanocytes for use in patients with stable vitiligo unresponsive to standard therapies.

Research paper thumbnail of Application of a filtration-and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma

Background: S ezary syndrome (SS), the leukemic form of cutaneous T-cell lymphoma (CTCL), has a p... more Background: S ezary syndrome (SS), the leukemic form of cutaneous T-cell lymphoma (CTCL), has a poor prognosis. Although no uniform standards for therapy of SS exist, preservation of the immune response through the use of extracorporeal photopheresis (ECP) and biologic therapies is associated with higher response rates compared to monotherapy. Purpose: Because predictors of response are poorly understood, we sought to identify the important prognostic parameters that affect overall response to treatment in SS. Design: We performed a retrospective cohort study of 143 patients who had a clinical and laboratory diagnosis of CTCL and were treated with ECP over a 25-year period at the University of Pennsylvania. Results: We identified 97 (67.8%) patients diagnosed with SS (stage III and IV with blood involvement), who completed at least 3 months of ECP and 1 or more systemic immunostimulatory agents (interferon-alfa, interferon-gamma, sargramostim, or systemic retinoids). A total of 73 (75.3%) patients had significant improvement with multimodality therapy: 30% had complete response (CR), defined as complete resolution of disease and 45% had partial response (PR) defined as greater than or equal to 50% improvement but less than 100%. The CR group compared to the NR group had a lower CD4:CD8 ratio (13.2 vs 44.2, P ¼ .04), median percent CD4 + /CD26 e (27.4 vs 57.2, P ¼ .01) and CD4 + /CD7 e (20 vs 41.3, P \.01) cells. Median monocyte percentage at initiation of therapy was higher for patients who showed a CR (9.5 vs 7.3, P ¼ .02). Differences between the CR and NR subgroup were not statistically significant for age at diagnosis, the median baseline white blood cell count, and serum lactate dehydrogenase. The PR group had a lower LDH, CD4 + /CD26 e percentage and CD4 + /CD7 e percentage (592 vs 707, 50.7 vs 57.2, and 36.4 vs 41.3, respectively). However, these variables were not statistically significant.

Research paper thumbnail of Melanoma of the Penis: A Clinical Dermoscopic Case Study

Acta Dermato Venereologica, 2010

Research paper thumbnail of Reply to: “Skin damage among health care workers managing coronavirus disease 2019”

Journal of the American Academy of Dermatology, 2020

Research paper thumbnail of EUREKA study - the evaluation of real-life use of a biophotonic system in chronic wound management: an interim analysis

Drug design, development and therapy, 2017

Interest has grown regarding photobiomodulation (PBM) with low-level light therapy, which has bee... more Interest has grown regarding photobiomodulation (PBM) with low-level light therapy, which has been shown to positively affect the stages of the wound healing process. In a real-life context clinical setting, the objective of the EUREKA study was to investigate efficacy, safety, and quality of life associated with the use of a BioPhotonic gel (LumiHeal™) in the treatment of chronic wounds such as venous leg ulcers (VLUs), diabetic foot ulcers (DFUs), and pressure ulcers (PUs). This BioPhotonic gel represents a new, first-in-class emission spectrum of light, including fluorescence, to induce PBM and modulate healing. The multicenter, prospective, interventional, uncontrolled, open-label study enrolled 100 patients in 12 wound centers in Italy. We performed an early interim analysis based on the first 33 subjects (13 VLU, 17 DFU, 3 PU) in seven centers who completed the study. Seventeen patients (52%) achieved total wound closure (full re-epithelialization for 2 weeks) during the study...

Research paper thumbnail of Epidermal skin grafting in vitiligo: a pilot study

International Wound Journal, 2016

Vitiligo is a multifactorial acquired dermatosis characterised by achromic or hypochromic macules... more Vitiligo is a multifactorial acquired dermatosis characterised by achromic or hypochromic macules and by the absence of functioning melanocytes. Treatment depends on the extent of the affected areas and on disease activity. Surgical techniques have proven to be effective in stable cases but can be time-consuming and, in some cases, aesthetically unsatisfying or painful for the patients. The aim of the study was to assess the clinical safety and effectiveness of a new automatic epidermal skin harvesting device in patients with stable localised vitiligo over a minimum 12-month period. This new system (CELLUTOME™ Epidermal Harvesting System, KCI, an ACELITY Company, San Antonio, TX) is a commercially available epidermal skin harvesting system that can be used without local anaesthesia or other pre-treatments and has been shown to have low rates of donor site morbidity. Epidermal skin grafts can used in patients with acute and hard to heal chronic wounds, burns and stable vitiligo. The use of advanced therapies may improve the quality of life, have cost benefits and accelerate re-pigmentation of patients with vitiligo. In our preliminary study, this system was seen to be a safe and efficacious means of harvesting epidermal micrografts containing melanocytes for use in patients with stable vitiligo unresponsive to standard therapies.

Research paper thumbnail of Application of a filtration-and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma

Background: S ezary syndrome (SS), the leukemic form of cutaneous T-cell lymphoma (CTCL), has a p... more Background: S ezary syndrome (SS), the leukemic form of cutaneous T-cell lymphoma (CTCL), has a poor prognosis. Although no uniform standards for therapy of SS exist, preservation of the immune response through the use of extracorporeal photopheresis (ECP) and biologic therapies is associated with higher response rates compared to monotherapy. Purpose: Because predictors of response are poorly understood, we sought to identify the important prognostic parameters that affect overall response to treatment in SS. Design: We performed a retrospective cohort study of 143 patients who had a clinical and laboratory diagnosis of CTCL and were treated with ECP over a 25-year period at the University of Pennsylvania. Results: We identified 97 (67.8%) patients diagnosed with SS (stage III and IV with blood involvement), who completed at least 3 months of ECP and 1 or more systemic immunostimulatory agents (interferon-alfa, interferon-gamma, sargramostim, or systemic retinoids). A total of 73 (75.3%) patients had significant improvement with multimodality therapy: 30% had complete response (CR), defined as complete resolution of disease and 45% had partial response (PR) defined as greater than or equal to 50% improvement but less than 100%. The CR group compared to the NR group had a lower CD4:CD8 ratio (13.2 vs 44.2, P ¼ .04), median percent CD4 + /CD26 e (27.4 vs 57.2, P ¼ .01) and CD4 + /CD7 e (20 vs 41.3, P \.01) cells. Median monocyte percentage at initiation of therapy was higher for patients who showed a CR (9.5 vs 7.3, P ¼ .02). Differences between the CR and NR subgroup were not statistically significant for age at diagnosis, the median baseline white blood cell count, and serum lactate dehydrogenase. The PR group had a lower LDH, CD4 + /CD26 e percentage and CD4 + /CD7 e percentage (592 vs 707, 50.7 vs 57.2, and 36.4 vs 41.3, respectively). However, these variables were not statistically significant.